Shaw and Partners Research Update: “Highly Encouraging Safety and Efficacy Data Further De-risks Cynata“

View the latest Shaw & Partners Research Update for Cynata Therapeutics

Download Report

This report has been prepared by Shaw and Partners Limited (AFSL 236 048) and solely reflects the views of Shaw and Partners.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Shaw and Partners at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.


Return To News